Abstract
Antineutrophil cytoplasmic antibody associated vasculitis includes granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis. While EGPA has no specific symptoms, it usually presents as necrotizing vasculitis, eosinophil infiltration of the tissues and organs, and extravascular granuloma formation. Here, we report a patient who had a rare initial presentation of oral granuloma and had been previously misdiagnosed several times at other hospitals. He was finally diagnosed with EGPA and recovered after methylprednisolone and cyclophosphamide treatment. The disease EGPA can present with a rare initial presentation of oral granuloma, methylprednisolone, and cyclophosphamide can be a suitable choice of treatment.
Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA), a necrotizing systemic vasculitis involving small and medium-sized vessels, is also known as Churg–Strauss syndrome or allergic granulomatous vasculitis. The age of disease onset ranges from 40 to 60 years (). More than 75% of EGPA patients present with sinusitis and asthma with associated eosinophilia (, ). Approximately 60% of patients have associated cardiac (), renal, or neurological involvement (). Patients with antineutrophil cytoplasmic antibody antineutrophil cytoplasmic antibody associated vasculitis (AAV) commonly have a poor prognosis. However, their 5-year survival rate can be improved to more than 70% after standardized immunotherapy (). We report a patient who had a rare initial presentation of oral granuloma and had been previously misdiagnosed several times at other hospitals. He was finally diagnosed with EGPA and recovered after appropriate immunosuppressive treatments.
Case Description
A 28-year-old male patient was admitted to the hospital after having oral pain for 1 month, skin ecchymosis with ulceration for 20 days, and abnormal renal function test results for 3 days. He had a medical history of chronic, untreated hepatitis-B for 18 years. One month prior to the admission, the patient began to experience oral pain. He was diagnosed with oral tuberculosis and received anti-tuberculosis treatment with rifampin and isoniazid, as well as appropriate analgesics when needed. He showed no improvement after 10 days of the treatment and developed ecchymosis and petechiae in both lower extremities. He was diagnosed with allergic purpura and received anti-allergic treatment with loratadine. Three days before coming to the hospital, he had shown no improvement with respect to oral pain or skin ecchymosis and had also developed foot ulcers. He returned to the hospital for further care.
After hospital admission, a physical examination revealed an anemic appearance, with no edema in the face or lower extremities. The patient had coarse breath sounds with wet rales on lung auscultation. There was a 5 cm × 5 cm grayish–white necrotic tissue bulging from the right side of the oral palate (Figure 1A). The lower extremities showed ecchymosis with skin ulceration and necrosis in the left toes (Figures 1B,C). Laboratory test results were as follows: Red blood cell count, 2.56 × 1012/L; hemoglobin, 67 g/L; eosinophils, 21.2%; serum albumin, 31.9 g/L; alanine aminotransferase, 81.3 U/L; aspartate aminotransferase, 106 U/L; serum creatinine, 538 μmol/L; uric acid, 584 μmol/L; cholesterol, 6.37 mmol/L; low-density lipoprotein, 4.06 mmol/L; C-reactive protein, 34.4 mg/L; hepatitis-B surface antigen HBsAg positive, hepatitis-B virus DNA <102, negative anti-nuclear antibody, and anti-double-stranded DNA antibody, normal serum immunoglobulin (Ig), IgA, IgM, and IgG, complement C3 and C4, and serum-free k- and λ-levels; normal serum anti-myeloperoxidase antibody level; and anti-proteinase 3 (PR3) antibody > 400 RU/ml. Urinary analysis showed urine protein 4+, urine microalbumin/creatinine 2,654 mg/g·Cr. A T-SPOT tuberculosis test and myocardial injury markers were negative. The oral ulcer smear was negative under acid-fast staining. Chest computerized tomography (CT) examination revealed bilateral multiple nodular shadows and pulmonary infection. Otolaryngoscopy suggested nasal mucosal erosion and necrosis. Sinus CT showed maxillary and ethmoid sinusitis. The Birmingham Vasculitis Activity Score was 27. Echocardiography showed mild mitral regurgitation. Electromyogram of extremities was unremarkable with normal sensory and motor functions.
Figure 1
Diagnostic Assessment
Pathological examination of the renal biopsy specimen showed that 2 of 14 glomeruli had global sclerosis. Two glomeruli had segmental necrosis of the capillary loops, with no cellular or fibrous crescents. There were extensive detachments of renal tubular epithelial cells and exposure of the basement membrane, with infiltration of small focal individual nucleated cells and eosinophils in the renal interstitium. The electron microscopic findings were consistent with the light microscopy findings. Immunofluorescence examination showed linear depositions of IgG(+) along the glomerular basement membrane, with negative staining for IgG1, IgG2, IgG3, IgG4, IgA, IgM, C3, C4, k, λ, and C1q. The final renal pathology diagnoses were acute tubulointerstitial kidney injury and antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with kidney injury (nodular necrotic lesions) (Figures 2A,B).
Figure 2
Based on the 2016 treatment guidelines for vasculitis issued by the European League Against Rheumatism, we administered methylprednisolone 40 mg/day and cyclophosphamide 0.6 g intravenously for 10 days. The patient showed gradual improvement, including less oral pain, reduced size of skin ulcers, the disappearance of ecchymosis, and healing toe ulcers. His serum creatinine also decreased to 125 μmol/L.
We followed up with this patient every 1–2 months and performed CT scanning and laryngoscopy at the second follow-up. Results suggested that pulmonary nodules dissipated and ethmoid sinusitis improved. There had been a total of eight follow-up visits to date. His symptoms have significantly improved. Furthermore, the vasculitis score decreased to 4. Serum PR3 was normalized and anemia was corrected. Serum creatinine and estimated glomerular filtration rate returned to normal. Urine microalbumin/creatinine decreased to <1,000 mg/g·Cr. Oral granuloma, foot ulcers, and nose and throat lesions were also healed (Figures 3A,B).
Figure 3
Discussion
Our patient presented with previously unreported oral granuloma as the first complaint. This atypical early presentation may have led to misdiagnosis as oral tuberculosis. With disease progression, this patient gradually developed more lesions in the skin, mucosa, lungs, kidneys, ear, nose, and throat, which led us to consider an immune disease with multisystem and multiorgan injuries.
According to 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggested, plasma exchange should be considered for patients with SCr > 5.7 mg/dl (500 mmol/L) requiring dialysis, for patients with rapidly increasing SCr, and for patients with diffuse alveolar hemorrhage who have hypoxemia (). The patient also had abnormal renal function as shown in the laboratory test, which could easily lead to misdiagnosis and mismanagement. Patients with ANCA-associated systemic vasculitis tend to have renal injuries, which present as abnormal renal function and crescentic and capillary loop necrosis. Initially, we considered that our patient had acute or chronic renal failure due to ANCA-mediated crescentic glomerulonephritis. However, the renal pathological examination did not support this initial diagnosis. The renal pathological changes not only included ANCA-mediated nodular necrotic lesions but also acute tubulointerstitial kidney injury, which might have been caused by previous analgesic intake and anti-TB treatment. Considering the renal pathology report, we lowered his vasculitis activity score from 27 to 24.
After confirming the diagnosis of this patient, we reviewed the 2021 KIDGO guidelines on the treatment of renal injury in ANCA-associated systemic vasculitis (), the 2016 treatment guidelines for the vasculitis from the European League Against Rheumatism (), and the stratified treatment strategy from the EGPA Five-Factor Score (). We decided to treat him with an induction therapy regimen including glucocorticoids at 1.0 mg/kg/day and cyclophosphamide at 0.6 g/month. Glucocorticoids were administered at a dose of 1.0 mg/kg/day for 1 month, after which they were gradually tapered off. During the maintenance therapy, glucocorticoids at 5–15 mg/day and cyclophosphamide at 0.6 g were given for 2 months. The patient's symptoms gradually improved during the 12-month follow-up period.
In summary, our patient had a confirmed diagnosis and his symptoms significantly improved after glucocorticoid and cyclophosphamide treatments. However, we were unable to make an accurate pathological diagnosis of oral granuloma because the patient declined oral biopsy. As such, we performed a laboratory and imaging examinations to exclude oral granulomas caused by tuberculosis, fungal infection, or thrombotic disease. However, the clinical improvement he showed after treatment suggested a close association between oral granuloma and primary disease. We learned two important lessons from the patient's presentations: (1) Performing renal biopsy and pathological examination is important in patients with ANCA-related systemic vasculitis and renal involvement because these patients can sustain renal injury from other causes mediated by factors unlike those of ANCA; (2) performing biopsy and pathological examination early is also important in patients with skin and mucosal granulomatous lesions to establish a clear diagnosis and prevent delays in treatment.
Funding
This work was supported by grants (cstc2019jscx-msxmX0166) from the Basic, Frontier Research Program of Chongqing and the Chongqing Talent Program Project (cstc2021ycjh-bgzxm0090) and Scientific Research Incubation Project of the Third Affiliated Hospital of Chongqing Medical University (KY20078).
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
LL and SG collected all the data, carried out the analysis of the patient's clinical course and outcome, and were also involved in drafting the manuscript. LZ and RY were responsible for the pathology images and legends. JY established the diagnosis and revised and approved the final manuscript. Each author contributed important intellectual content during the drafting and revision of the manuscript. All authors have read and approved the final version of the manuscript to be published.
Acknowledgments
We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- ANCA
antineutrophil cytoplasmic antibody
- AAV
antibody associated vasculitis
- GPA
granulomatosis with polyangiitis
- EGPA
eosinophilic granulomatosis with polyangiitis
- MPA
microscopic polyangiitis
- PR3
anti-proteinase 3.
Abbreviations
References
1.
GioffrediAMaritatiFOlivaEBuzioC. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. (2014) 5:549–55. 10.3389/fimmu.2014.00549
2.
YilmazITutarNSimşekZÖOymakFSGülmezI. Clinical and serological features of eosinophilic and vasculitic phases of eosinophilic granulomatosis with poliangiitis: a case series of 15 patients. Turk Thorac J. (2017) 18:72–77. 10.5152/TurkThoracJ.2017.16040
3.
SecciaVBaldiniCLatorreMGelardiMDallanICristofani-MencacciLet al. Focus on the involvement of the nose and paranasal sinuses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): nasal cytology reveals infiltration of eosinophils as a very common feature. Int Arch Allergy Immunol. (2018) 175:61–9. 10.1159/000484602
4.
CeredaAFPedrottiPDe CapitaniLGiannattasioCRoghiA. Comprehensive evaluation of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac magnetic resonance. Eur J Intern Med. (2017) 39:51–6. 10.1016/j.ejim.2016.09.014
5.
SalvadorF. ANCA associated vasculitis. Eur J Intern Med. (2020) 74:18–28. 10.1016/j.ejim.2020.01.011
6.
ScottDGIWattsRA. WattsEpidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol. (2013) 17:607–10. 10.1007/s10157-013-0830-8
7.
KidneyDisease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2021 Clinical Practice Guideline on glomerular disease. Kidney International. (2021) 100:S1–S276. 10.1016/j.kint.2021.05.021
8.
YatesMWattsRABajemaIMCidMCCrestaniBHauserTet al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. (2016) 75:1583–94. 10.1136/annrheumdis-2016-209133
9.
French Vasculitis Study Group (FVSG). The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. (2011) 90:19–27. 10.1097/MD.0b013e318205a4c6
Summary
Keywords
eosinophilic granulomatosis with polyangiitis, case report, antineutrophil cytoplasmic antibody, ANCA-associated vasculitis (AAV), myeloperoxidase
Citation
Lin L, Yu R, Zheng L, Gong S and Yang J (2022) Eosinophilic Granulomatosis With Polyangiitis Presenting With Oral Granuloma as the Initial Symptom: A Case Report. Front. Med. 9:842137. doi: 10.3389/fmed.2022.842137
Received
23 December 2021
Accepted
08 April 2022
Published
10 May 2022
Volume
9 - 2022
Edited by
Gian Marco Ghiggeri, Giannina Gaslini Institute (IRCCS), Italy
Reviewed by
Wei Zhou, Capital Medical University, China; Mark Dominik Alscher, Robert Bosch Hospital, Germany
Updates
Copyright
© 2022 Lin, Yu, Zheng, Gong and Yang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jurong Yang 650230@hospital.cqmu.edu.cn
This article was submitted to Nephrology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.